Medicare Drug Plan Costs to Rise 50% in 2027, Experts Warn
Medicare prescription drug premiums are set to surge 50% in 2027, making open enrollment decisions more critical than ever.
Medicare prescription drug costs are projected to climb sharply in 2027, with beneficiaries facing potential premium increases of roughly 50%, according to a report from MarketWatch. The coming spike underscores the financial stakes for the tens of millions of Americans enrolled in Medicare Part D plans.
Experts warn that staying passive during open enrollment — the annual window when beneficiaries can switch, drop, or add coverage — could leave retirees and disabled Americans locked into plans that no longer offer competitive pricing or adequate drug coverage. The cost of inaction, in this context, is measurable in real dollars.
Read more Medicare Advantage vs. Traditional Medicare: Key Differences Explained →
Open enrollment periods are specifically designed to give beneficiaries flexibility to respond to exactly these kinds of market shifts. Failing to compare available plans each year means risking automatic re-enrollment in a plan whose premiums or formularies may have changed significantly to a beneficiary's disadvantage.
Financial advisers and Medicare counselors broadly recommend that enrollees review their current Part D plans annually, compare alternatives through the Medicare Plan Finder tool, and assess whether their specific medications remain covered at favorable cost-sharing tiers under any plan they are considering.
With a 50% cost increase on the horizon, the 2027 coverage year will represent one of the more consequential open enrollment cycles in recent memory for Medicare drug plan participants. Continue reading at MarketWatch.com
